Skip Navigation
Search

 

Welcome to the Ojima Research Group Website

Synthetic Organic and Medicinal Chemistry at the Biomedical Interface

main

Discovery and development of new and potent anticancer agents, antibacterial agents, anti-inflammatory agents, and various enzyme inhibitors are the major research interests in Professor Ojima's laboratory. Integration of all relevant chemistry and biological tools, including computational biology (docking, in silico screening, molecular dynamics), chemical biology (protein expression, enzyme assays, fluorescence labeling), cell biology (cell culture, cytotoxicity assay, fluorescent confocal microscopy, flow cytometry, transmission and scanning electron microscopy), has successfully been realized in this program. Naturally, this research program is promoted in close collaboration with cell biologists, oncologists, microbiologist, pharmacologists, hematologists, toxicologists, etc., as well as the  Division of Laboratory Animals Resources for in vivo efficacy evaluations. The Ojima Laboratory has also been exploring and developing new synthetic methodologies, especially based on catalytic organic transformations, including enantioselective processes, cyclohydrocarbonylations and higher order cycloadditions and carbocyclizations, which provide the basis for the efficient syntheses of biologically active substances of medicinal interest, such as those anticancer and antibacterial agents mentioned above.

 

Ojima Research Group 2024

group 2024

News

Congratulation to Dr. Ashna Garg for successfully defending her thesis!

Dr. Garg


Katie Shou and Prof. Ojima were featured in the Stony Brook Magazine

katie


Congratulations to Simon's Summer Research students Katie Shou, Allyson Wong and Elizabeth Xiu for finishing the program!

simons


Congratulations to Dr. Kalani Jayanetti for successfully defending her thesis!

Dr. Jayanetti


ART26.12, an anti-nociceptive compound originally developed at Stony Brook in collaboration between the Ojima and Kaczocha groups, was given initial approval by the FDA to start human phase 1 trials!

fda


Congratulations to our graduates Ashna Garg, Kalani Jayanetti, Jacob Acosta, Binna Chen, Saba Gulzar and Yuxuan Zhang!

Commencement


The Ojima Distinguished Lectureship Award was presented to Prof. Hikoaki Suga

Suga

More News

Research

Next-Generation Pain Control with Novel Stony Brook Fatty Acid Binding Protein (FABP) Inhibitors (SB-FIs)FABP


FABP Inhibitors (SB-FIs) as New-Generation Anticancer Agents

path


Novel Antifungal AcylhydrazonesAcylhydrazones


Sterylglucosidase Inhihibitors as Novel Antifungal AgentsSterylglucosidase


Next-Generation Taxoids as Potent and Efficacious Anticancer Agents

taxoids


Tumor-Targeted Delivery of Highly Potent Taxoid Anticancer Agentstumor targeting